Trial Condition(s):

Ophthalmology, Macular Degeneration

A follow-up physician survey to evaluate physician knowledge of safety and safe use information for Aflibercept administered by intravitreal injection in Europe

Bayer Identifier:

20285

ClinicalTrials.gov Identifier:

NCT04067583

EudraCT Number:

Not Available

EU CT Number:

Not Available

Study Completed

Trial Purpose

With this follow up physician survey researcher want to collect the same data from all participants of the study using a highly structured questionnaire. The questionnaire will gather information related to physician characteristics and experience with Aflibercept, as well as assess physicians’ knowledge and understanding of storage and preparation, proper injection technique, and the risks associated with Aflibercept injection into the eye (intravitreal injection). Analysis will be done using descriptive statistics.

Inclusion Criteria
- Has signed informed consent
- Is a licensed and practicing ophthalmologist
- Has prescribed and/or administered aflibercept to at least one patient in the past 6 months
Exclusion Criteria
- None

Trial Summary

Enrollment Goal
454
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
No
Products
Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
Accepts Healthy Volunteers
Yes

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Many locations

Many locations, Germany

Status
Completed

Trial Design